George Health Enterprises and its subsidiary George Medicines have raised a combined $35m in funding from investors including Bupa Australia to drive pipeline development and commercialisation.

George Health Enterprises and its subsidiary George Medicines have raised a combined $35m in funding from investors including Bupa Australia to drive pipeline development and commercialisation.

Bristol Myers Squibb and Otsuka Pharmaceutical were among the limited partners for what LSP said is Europe's largest ever life sciences VC fund.

The Spain-based energy utility is set to contribute approximately $23m to the vehicle, which will invest in renewable energy technology developers.

The cancer immunotherapy developer has closed a $23.6m round featuring 3SBio Group and Eisai, both of which have signed collaboration agreements with it in recent months.

Rocket Internet-backed Goodlord has taken its total funding past $22m having raised more than $12.4m in a round led by venture firm Finch Capital.

The vehicle will back early-stage life sciences proposals from Utrecht province with support from both UMC Utrecht and Utrecht University.

Imperial College London has opened a new funding stream for its early-stage research with the launch of its Parkwalk Advisors-managed Innovation Fund.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Neil Woodford could return to the stage with a bid for some of his old assets should ongoing talks with unnamed UK-based institutional investors and wealth managers succeed.